- Janet Clennett, CPA, has been named as Vice President, Finance
- Roger Davies, B.Sc., M. Phil, joins Aptose as Vice President, Operations
- Clennett’s experience also includes participation in and support of multiple financing transactions and clinical programs
- Roger Davies brings to Aptose more than 25 years of senior clinical project management experience, including a decade of oncology-focused experience
- Aptose Biosciences Inc. (APS) is up 0.75 per cent, trading at C$2.70 at 2:39 pm ET
Aptose Biosciences (TSX: APS) has appointed two key members to its management team to support its finance and operations functions.
Janet Clennett, CPA, has been named to Vice President, Finance; and Roger Davies, B.Sc., M. Phil, joins Aptose as Vice President, Operations.
With more than 15 years of experience in finance and accounting disciplines at publicly traded early-stage biotechnology companies, Janet Clennett joined Aptose in 2017 as Director of Finance and she continues to oversee financial operations, including financial reporting and accounting.
Her experience also includes participation in and support of multiple financing transactions and clinical programs. Prior, Clennett was Director of Finance and Acting CFO at ProMIS Neurosciences, and Controller and Chief Financial Officer at Fralex Therapeutics. She is a Chartered Professional Accountant (CPA) and a graduate of the University of Waterloo, Canada.
Roger Davies brings more than 25 years of senior clinical project management experience to Aptose, including a decade of oncology-focused experience and extensive knowledge of clinical development of both solid and hematological tumours, as well as metabolic diseases.
In the role of Vice President, Operations, Roger will manage oversight of Aptose’s general operations, including human resources, cross-functional communications, information technology and project management.
Roger Davies has been responsible for project management teams and global Phase 3 studies, as well as Phase 1 and Phase 2 clinical trials, at major CROs including IQVIA, Syneos, and ICON; and at small and large biotechnology companies, including Lexicon Pharmaceuticals, Intercept Pharmaceuticals, Celgene and Novartis.
Davies has a degree in Physiology from the University of Newcastle-upon-Tyne, England, and a Master of Philosophy degree (M.Phil.) in physiology from the University of Edinburgh, Scotland.
“Janet and Roger bring vast track records in finance, operations and communications functions and expand our foundation to support Aptose’s growth and clinical expansion plans for our targeted oncology pipeline,” said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer.
“We are delighted to welcome them to the leadership team,” concluded Rice.
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology.
Aptose Biosciences Inc. (APS) is up 0.75 per cent, trading at C$2.70 at 2:39 pm ET.
